Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic obstructive pulmonary disease

J M Madison1, R S Irwin

  • 1Pulmonary, Allergy, and Critical Care Medicine Division, University of Massachusetts Medical School, Worcester 01655, USA.

Lancet (London, England)
|August 26, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Noncoding RNAs connect genetic risk factors to the neurodevelopmental basis of bipolar disorder.

Molecular psychiatry·2015
Same author

Characterization of bipolar disorder patient-specific induced pluripotent stem cells from a family reveals neurodevelopmental and mRNA expression abnormalities.

Molecular psychiatry·2015
Same author

Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons.

Molecular psychiatry·2015
Same author

Dysregulation of miR-34a links neuronal development to genetic risk factors for bipolar disorder.

Molecular psychiatry·2015
Same author

Functional implications of a psychiatric risk variant within CACNA1C in induced human neurons.

Molecular psychiatry·2014
Same author

Cis-acting regulation of brain-specific ANK3 gene expression by a genetic variant associated with bipolar disorder.

Molecular psychiatry·2012
Same journal

Convergence of metabolic risk in obesity and normal BMI: does risk disappear?

Lancet (London, England)·2026
Same journal

Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies.

Lancet (London, England)·2026
Same journal

Safety and efficacy of mRNA vaccines: a mechanistic and public health perspective.

Lancet (London, England)·2026
Same journal

The US Ebola response and the future of global health leadership.

Lancet (London, England)·2026
Same journal

Daniel Mason: a tale of change.

Lancet (London, England)·2026
Same journal

The 2026 Wakley-Wu Lien Teh Prize Essay: why medicine, and why stay?

Lancet (London, England)·2026
See all related articles

Acute exacerbations of chronic obstructive pulmonary disease (COPD) require prompt management. Key treatments include oxygen, bronchodilators, corticosteroids, antibiotics, and ventilation for severe cases to improve patient outcomes.

Area of Science:

  • Pulmonology
  • Critical Care Medicine

Background:

  • Acute exacerbations are a primary cause of respiratory decline in COPD patients.
  • Despite preventive advancements, hospital admissions for exacerbations remain frequent.
  • Existing expert guidelines highlight a need for more robust clinical studies on exacerbation management.

Purpose of the Study:

  • To outline the essential components of managing acute exacerbations in COPD patients.
  • To address controversies in COPD exacerbation treatment based on current evidence.

Main Methods:

  • Review of controlled clinical trials and expert consensus guidelines.
  • Emphasis on clinical assessment and evidence-based therapeutic interventions.

Main Results:

Related Experiment Videos

  • Controlled trials support specific management strategies for COPD exacerbations.
  • Evidence supports the use of supplemental oxygen, inhaled bronchodilators, corticosteroids, and antibiotics.

    • Conclusions:

    • Careful clinical assessment is crucial for managing acute COPD exacerbations.
    • Non-invasive positive-pressure ventilation is beneficial for selected patients with acute ventilatory failure.
    • Further research is needed, but current evidence guides effective treatment of COPD exacerbations.